Cancer prevention research small grant program (R03).
The NCI Division of Cancer Prevention invites applications that address developmental research in chemoprevention agent development, biomarkers, early detection, and nutrition science, in addition to clinical studies that focus on specific target organs. This scientific initiative (funding opportunity) is not intended for the support of research grant applications that are focused on treatment, etiology, and/or treatment-related general quality of life studies that are population based. The specific areas of research may include, but are not limited to:
Early detection. 1) identification, development, and evaluation of biological analytic techniques, methodologies, and clinical technologies relevant to preclinical cancer detection and prevention of primary and recurrent cancers; 2) cellular, molecular, and genetic tumor markers; 3) molecular epidemiology and genetic risk factors; 4) imaging technology; 5) identification of molecular signatures of cancerassociated infectious agents for earlier cancer detection and risk assessment; 6) transfer of basic laboratory findings into applications for early detection with the goal of extending this research to comparative clinical trials; 7) development and evaluation of new high-throughput genomic-and proteomic-based detection techniques as well as of measures of sensitivity, specificity, validity, and safety; 8) performance of translational research to facilitate the transfer of new technologies (to the clinical setting) for earlier detection, prevention, and risk assessment; 9) development and evaluation of computer-based data monitoring systems for analysis and interpretation of laboratory data on multiple markers of and for the development of modeling systems based on molecular, genetic, and other risk factors to be used in the evaluation of cancer prevention approaches; 10) definition and evaluation of prognostic factors of precancerous lesions by computer models that include neural networks, artificial intelligence, and other techniques; and 11) development of analytic techniques to identify populations that may be at increased risk as indicated by genetic and metabolic phenotypes (susceptibility markers).
Chemoprevention. 1) pilot testing and development of new methods of chemoprevention, dietary, or nutrition intervention; 2) development and evaluation of molecular targets to prevent, reverse, or retard progression of precancerous lesions (and hence the cancer process) by natural, synthetic, chemopreventive agents; 3) feasibility and efficacy testing of rapid screening methods to identify and prioritize new chemopreventive agents; 4) testing of new strategies to prevent cancer or its progression in persons at increased genetic risk; 5) development of innovative animal models to mimic the human cancer process in order to expedite research in cancer prevention; and 6) investigation of mechanisms of action of chemopreventive agents.
Nutrition. 1) improvements in methodology development for assessing nutritional status, metabolic patterns, and dietary modulation of genetic expression; 2) identification, development, and validation of biochemical or biological markers for measuring and monitoring dietary compliance and exposure; 3) development of reliable methods for analysis of nutrients, other dietary components, and their metabolites in foods, body fluids, and tissues; 4) development of mechanistic studies of dietary constituent interactions, gene-nutrient interactions, and dietary environmental factor interactions; 5) identification and evaluation of molecular targets to prevent, reverse, or retard progression of precancerous lesions (and hence the cancer process) by dietary/nutritional interventions; 6) determination of bioavailability and dose response of foods, nutrients, and other naturally occurring food constituents; and 7) although the specific study proposed may attempt only to obtain preliminary data and/or conduct pilot studies in support of a future, more detailed clinical study, it is important that a long-term human cancer prevention hypothesis and supporting scientific justification be presented.
This program is designed to increase the basic and applied scientific knowledge of cancer prevention research, and to enhance community-based clinical research in cancer prevention.
The common characteristic of the NIH R03 small grant is provision of limited funding for a short period of time. Examples of the types of projects that NIH ICs support with the R03 include the following: 1) pilot or feasibility studies; 2) secondary analysis of existing data; 3) small, self-contained research projects; 4) development of research methodology; 5) development of new research technology; 6) nature of the research opportunity; 7) pertinent background information that establishes the need for the research; 8) scientific knowledge to be achieved through research supported by the special program; 9) objectives of this research program; and 10) identification of the types of research and experimental approaches being sought to achieve the objectives.
This Funding Opportunity Announcement (FOA) will use the NIH Small Grants Program (R03) award mechanism. As an applicant, you will be solely responsible for planning, directing, and executing the proposed project. The total budget may not exceed $100,000 in direct costs for the entire project. The direct costs in any one year must not exceed $50,000. Please note that facilities and administrative [F&A] costs requested by any consortium participants are excluded from the direct cost limit per NIH Guide Notice NOT-OD-04- 040 (http://grants.nih.gov/grants/guide/notice-files/ NOT-OD-04-040.html).
The total project period for an application submitted in response to this program announcement may not exceed 2 years. NIH policy limits the number of amendments that may be submitted to two. The small grant is not renewable.
This FOA uses just-in-time concepts. It also uses the modular budget formats (see the "Modular Applications and Awards" section of the NIH Grants Policy Statement). Specifically, if you are submitting an application with direct costs in each year of $250,000 or less (excluding consortium Facilities and Administrative [F&A] costs), use the PHS398 Modular Budget component provided in the SF424 (R&R) Application Package and SF424 (R&R) Application Guide (see specifically Section 5.4, "Modular Budget Component," of the Application Guide).
Applicants must download the SF424 (R&R) application forms and SF424 (R&R) Application Guide for this FOA through Grants.gov/Apply.
Note: Only the forms package directly attached to a specific FOA can be used. You will not be able to use any other SF424 (R&R) forms (e.g., sample forms, forms from another FOA), although some of the "Attachment" files may be useable for more than one FOA.
For further assistance, contact GrantsInfo, 301- 435-0714, (telecommunications for the hearing impaired: TTY 301-451-0088), or by e-mail: GrantsInfo@nih.gov.
The application submission dates for this PAR are 21 July 2007, and 20 December 2007.
Contacts: The complete list of agency contacts is available at http://grants.nih.gov/grants/guide/pafiles/ PAR-06-313. Reference: PAR-06-313.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Fellowships, Grants, & Awards|
|Publication:||Environmental Health Perspectives|
|Date:||Aug 1, 2007|
|Previous Article:||Another test for lead effects: early childhood exposure influences end-of-grade scores.|
|Next Article:||Translational research for the prevention and control of diabetes and obesity (R18).|